One of the key advantages of Amprologix' work is the use of Artificial Intelligence to accelerate research.
By partnering with STFC (Science & Technology Facilities Council), Amprologix is able to utilize cutting-edge machine learning algorithms to improve antibiotic properties.
Gordon is a serial entrepreneur who has helped negotiate co-development / licensing deals with numerous pharmaceutical majors and helped found and manage a number of University biotech spinouts, including: Microbiosensor, Conformetrix, Ai2 and Gentronix.
Matt is a professor of Medical Microbiology at the University of Plymouth and co-founder of Amprologix. Matt discovered the NI01 peptide family whilst working at Manchester University. Matt is also a founder and director of University of Manchester spinout company Spectromics.
Ian is the MD and co-founder of industrial biotechnology company Ingenza Ltd. Ian and Ingenza bring unique expertise in synthetic biology and production strain optimization to Amprologix.